Shift Bioscience
Cambridge
About Shift Bioscience
Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high-throughput, high-accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes accessible by simple prescription.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $16.3M
- Funding stage: Seed
- Last round: Seed (Oct 2024)
- Website: shiftbioscience.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Machine Learning, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/shift-bioscience-7882 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.